Journal of Clinical Pharmacy and Therapeutics, 2014
doi: 10.1111/jcpt.12218
Intravenous iron administration is associated with reduced platelet counts in patients with chronic kidney disease A. M. Hazara* MBBS MRCP and S. Bhandari*† MBChB MClinEdu PhD FRCP *Department of Renal of Medicine, Hull and East Yorkshire Hospitals NHS Trust, Kingston-upon-Hull, and †Hull York Medical School, Kingston-upon-Hull, UK
Received 11 June 2014, Accepted 10 September 2014
Keywords: chronic kidney disease, chronic kidney disease, iron, platelet, renal anaemia
(ESA) has been shown to further compound problems.6 New anaemia management strategies that might also help reduce the heavy burden of cardiovascular and thromboembolic events in patients with CKD are urgently needed. In this context, the effects of intravenous (i.v.) iron therapy on platelet counts (PLT) represent a novel avenue of further research as thrombocytosis is considered to be a risk factor for venous thromboembolism (VTE).7,8 In patients with chemotherapy-induced anaemia receiving ESA therapy, the use of i.v. iron resulted in significantly lower PLT and fewer VTEs in comparison with those treated with oral iron or no additional treatment.9 Previous reports in the literature have linked administration of i.v. iron with possible reduction in PLT in patients with CKD. In an editorial article, Dahl et al.10 have reported results of a post hoc analysis from the Dialysis Patients’ Response to Intravenous Iron with Elevated Ferritin (DRIVE) study.11 In the DRIVE study, 134 patients on haemodialysis with serum haemoglobin (Hb)
doi: 10.1111/jcpt.12218
Intravenous iron administration is associated with reduced platelet counts in patients with chronic kidney disease A. M. Hazara* MBBS MRCP and S. Bhandari*† MBChB MClinEdu PhD FRCP *Department of Renal of Medicine, Hull and East Yorkshire Hospitals NHS Trust, Kingston-upon-Hull, and †Hull York Medical School, Kingston-upon-Hull, UK
Received 11 June 2014, Accepted 10 September 2014
Keywords: chronic kidney disease, chronic kidney disease, iron, platelet, renal anaemia
(ESA) has been shown to further compound problems.6 New anaemia management strategies that might also help reduce the heavy burden of cardiovascular and thromboembolic events in patients with CKD are urgently needed. In this context, the effects of intravenous (i.v.) iron therapy on platelet counts (PLT) represent a novel avenue of further research as thrombocytosis is considered to be a risk factor for venous thromboembolism (VTE).7,8 In patients with chemotherapy-induced anaemia receiving ESA therapy, the use of i.v. iron resulted in significantly lower PLT and fewer VTEs in comparison with those treated with oral iron or no additional treatment.9 Previous reports in the literature have linked administration of i.v. iron with possible reduction in PLT in patients with CKD. In an editorial article, Dahl et al.10 have reported results of a post hoc analysis from the Dialysis Patients’ Response to Intravenous Iron with Elevated Ferritin (DRIVE) study.11 In the DRIVE study, 134 patients on haemodialysis with serum haemoglobin (Hb)
